Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT05908786
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇺🇸University of Southern California (USC); Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica, California, United States
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 650
- Registration Number
- NCT05904886
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸UCLA MEDICAL CENTER; Alhambra, Alhambra, California, United States
🇺🇸UCSF Fresno at Community Cancer Institute, Clovis, California, United States
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 230
- Registration Number
- NCT05894239
- Locations
- 🇺🇸
Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2000
- Registration Number
- NCT05878769
- Locations
- 🇦🇷
Fundacion Scherbovsky, Mendoza, Argentina
🇦🇷Centro Respiratorio Quilmes, Quilmes, Argentina
🇧🇬Medical Center New rehabilitation center EOOD, Stara Zagora, Bulgaria
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
- Conditions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1200
- Registration Number
- NCT05872763
- Locations
- 🇨🇳
Beijing Chest Hospital; Oncology Department, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China
🇨🇳Sichuan Provincial Cancer Hospital, Chengdu, China
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT05861986
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸Cook Children's Jane and John Justin Neurosciences Center, Fort Worth, Texas, United States
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT05861999
- Locations
- 🇺🇸
Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Children's Hospital of the King's Daughter, Norfolk, Virginia, United States
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT05862285
- Locations
- 🇨🇷
Clinica CIMCA, San José, Costa Rica
🇨🇳Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan
🇲🇽Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT05852691
- Locations
- 🇺🇸
Cancer Blood and Specialty Clinic, Los Alamitos, California, United States
🇺🇸Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, California, United States
🇺🇸UCSF Comprehensive Cancer Ctr, San Francisco, California, United States
A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 466
- Registration Number
- NCT05846594
- Locations
- 🇫🇷
Centre Oscar Lambret; Chir Cancerologie General, Lille, France
🇫🇷Hopital Marie Lannelongue, Le Plessis Robinson, France
🇫🇷Institut Sainte Catherine;Recherche Clinique, Avignon, France